DISC MEDICINE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.86 USD | -3.05% |
|
+12.94% | -22.33% |
| 17/06 | BMO Capital Adjusts Price Target on Disc Medicine to $70 From $50, Maintains Outperform Rating | MT |
| 14/06 | Wedbush Raises Disc Medicine Price Target to $57 From $43, Maintains Outperform Rating | MT |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 133.08Cr 11TCr |
|---|---|---|---|---|---|
| Net income 2024 * | -12Cr -992.58Cr | Net income 2025 * | -14Cr -1.2TCr | EV / Sales 2024 * | - |
| Net cash position 2024 * | 42Cr 3.54TCr | Net cash position 2025 * | 42Cr 3.5TCr | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-9.77
x | P/E ratio 2025 * |
-8.49
x | Employees | 78 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 68.28% |
More Fundamentals
* Assessed data
More news
Latest transcript on Disc Medicine, Inc.
More recommendations
More press releases
| 1 day | -3.05% | ||
| 1 week | +12.94% | ||
| Current month | +32.14% | ||
| 1 month | +39.40% | ||
| 3 months | -27.39% | ||
| 6 months | -23.60% | ||
| Current year | -22.33% |
1 week
38.22
48.45
1 month
30.6548.45
Current year
25.6077.60
1 year
25.6077.60
3 years
15.0077.60
5 years
15.0077.60
10 years
15.0077.60
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 32 M€ | +4.18% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/24/17 | 44.86 | -3.05% | 1,036,792 |
| 14/24/14 | 46.27 | +18.16% | 1,199,838 |
| 13/24/13 | 39.16 | +0.80% | 183,870 |
| 12/24/12 | 38.85 | -0.72% | 229,054 |
| 11/24/11 | 39.13 | -1.49% | 174,988 |
Delayed Quote Nasdaq, June 18, 2024 at 01:30 am IST
More quotes
Disc Medicine, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps) including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
Calendar
09/08/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
44.86
USD
Average target price
64.33
USD
Spread / Average Target
+43.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.33% | 133.08Cr | |
| +38.66% | 5.28TCr | |
| -7.81% | 3.89TCr | |
| +35.60% | 3.82TCr | |
| -10.77% | 2.68TCr | |
| +11.77% | 2.62TCr | |
| -17.82% | 1.99TCr | |
| +35.09% | 1.32TCr | |
| +29.17% | 1.22TCr | |
| -3.05% | 1.18TCr |
- Stock Market
- Equities
- IRON Stock
